FDA Advisory Panel Recommends Approval Of Merck’s Hepatitis C Treatment Victrelis

A Food and Drug Administration advisory panel April 27 voted unanimously to recommend that FDA approve Merck & Co.'s Victrelis (boceprevir) for the treatment of patients with chronic hepatitis C virus.

The Antiviral Drugs Advisory Committee voted 18 to 0 that the available data support approval of Victrelis for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1 infection in combination with pegylated interferon and ribavirin, an FDA spokeswoman told BNA April 28.

Victrelis is one of a new class of medicines known as HCV protease inhibitors being evaluated by FDA for the treatment of chronic HCV ...